semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Breast Cancer patients with first treated or recurrent metastatic breast cancer, according to version 1.1 standard, confirmed by CT or MRI, have at least one measurable lesion HER2 positive or triple negative patients; (IHC++, fish amplification) Patients with anti-HER2 treatment as first-line or not, and patients with HER2 positive can be treated with adjuvant therapy containing trastuzumab
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer ER-positive and/or PR-positive breast cancer HER2-negative breast cancer Unresectable locally advanced or metastatic breast cancer Confirmed disease progression while in the last aromatase inhibition-containing regimen in the metastatic setting At least one taxane or anthracycline regimen in either the adjuvant or the neoadjuvant setting Patients with no prior line of chemotherapy in the metastatic setting At least 1 and up to 3 prior lines of endocrine therapy in the metastatic setting ECOG score 0 or 1 Patients have adequate bone marrow and organ function Patients must have measurable disease (RECIST v.1.1)  Have received radiation therapy or limited-field palliative radiotherapy within two weeks prior to Cycle 1, Day 1, or patients who have not recovered from radiotherapy-related toxicities Have received prior chemotherapy for locally advanced or metastatic disease Have peripheral neuropathy grade 2 or greater QTc > 480 msec on basal assessments, history of congenital or personal history of long QT syndrome, Brugada syndrome, or Torsade de Pointes (TdP), or uncontrolled electrolyte disorders Child-bearing potential women not using highly effective methods of contraception Known hypersensitivity to eribulin, endocrine therapy or its excipients Other malignancies within the previous two years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of cervix or breast Known uncontrolled metastases to the central nervous system (CNS) or any progressing CNS disease Have a serious concomitant systemic disorder incompatible with the study Major surgical procedure or significant traumatic injury within 28 days prior to randomization
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Triple Negative Breast Cancer Early-stage Breast Cancer HER2-positive Breast Cancer The patient must have consented to participate and must have signed and dated an appropriate IRB-approved consent form that conforms to federal and i institutional guidelines for the pre-entry research core biopsy for CELx HSF testing and for initiating chemotherapy Patients must be female Patients must be ≥ 18 years old Patient must have an ECOG performance status of 0 or 1 The diagnosis of invasive adenocarcinoma of the breast must have been made by core needle biopsy The primary breast tumor must be palpable and measure ≥ 1.0 cm on physical exam The regional lymph nodes can be cN0 or cN1 The tumor size can be T1c or T2 Ipsilateral axillary lymph nodes must be evaluated by imaging (mammogram, ultrasound, and/or MRI) within 6 weeks prior to initiating chemotherapy. If suspicious or abnormal, FNA or core biopsy is recommended, also within 6 weeks prior to initiating chemotherapy. Findings of these evaluations will be used to determine the nodal status prior to initiating chemotherapy Nodal status  T3 or T4 tumors including inflammatory breast cancer FNA alone to diagnose the breast cancer Excisional biopsy or lumpectomy performed prior to initiating chemotherapy Surgical axillary staging procedure prior to initiating chemotherapy. Pre neoadjuvant therapy sentinel node biopsy is not permitted. (FNA or core biopsy is acceptable.) Definitive clinical or radiologic evidence of metastatic disease. Required imaging studies must have been performed within 6 weeks prior to initiating chemotherapy Synchronous bilateral invasive breast cancer. (Patients with synchronous and/or previous contralateral DCIS or LCIS are eligible.) Any previous history of ipsilateral invasive breast cancer or ipsilateral DCIS. (Patients with synchronous or previous ipsilateral LCIS are eligible.) Previous therapy with anthracycline, taxanes, trastuzumab, or other HER2 targeted therapies for any malignancy Any sex hormonal therapy, e.g., birth control pills, ovarian hormone replacement therapy, etc. (These patients are eligible if this therapy is discontinued prior to initiating chemotherapy.)
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Female patients with a histological diagnosis of breast cancer with known HER2 status ((8 positive and 8 negative). 2. Written informed consent prior to admission in the study. 3. Target lesion diameter of ≥15mm that has not been previously irradiated. 4. Female patients aged ≥ 18 years of age. 5. For all patients: histologically confirmed locally advanced/metastatic breast cancer with a biopsy within the last 12 months confirming HER2 status by either immunohistochemistry (IHC), Silver In Situ Hybridization (SISH) or Fluorescent In Situ Hybridization (FISH). 6. ECOG performance status 0-2 7. Negative urine pregnancy test (within 2 hours prior to injection of imaging agent) in women of child bearing age and willingness to use contraception (barrier, abstinence, non-hormonal) for 3 weeks after injection of [18F]GE-226 8. Life expectancy > 3 months 9. Adequate organ function as defined by Hb≥10g/L WBC≥3.0 x 109/L PLT≥80 x 109/L Serum creatinine ≤1.4mg/dl SGOT and SGPT ≤2 x ULN Total bilirubin ≤ 2 x ULN or 3.0 mg/dl in patients with Gilbert's syndrome 10. Patients must have been appropriately staged using FDG-PET within 42 days of study entry and additional imaging according to local standard of care  Pregnant or lactating women. 2. History of cardiac disease (myocardial infarction, arrhythmias requiring therapy, symptomatic valvular disease, cardiomyopathy, or pericarditis). 3. Evidence of significant medical condition or laboratory finding which, in the opinion of the Investigator, makes it undesirable for the patient to participate in the trial. 4. Participants with severe claustrophobia or who are unable to lie flat or fit into the scanner (≥350 lbs (160 Kg)). 5. Prior use within 14 days of enrolment or concurrent therapy with any other investigational agent. 6. Patients classified as radiation workers 7. Patients on therapeutic doses of anticoagulants, or with a raised prothrombin time
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Bile Duct Neoplasms Intraductal Papillary Mucinous Neoplasm Clinical diagnosis of IPNBs ECOG Performance status of 0, 1, or 2 Adequate liver function, bilirubin < 1.5 times ULN, ALT or AST < 2.5 times ULN Adequate renal function: creatinine < 1.8 Must be at least 18  Diagnosis of hepatic mucinous cystadenoma (MCN) Complicated with other Malignancy Pregnancy
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Relationship and Consistency Analysis breast cancer in stage I-III, tumor size>0.5cm 2. lymph nodes negative 3. hormone receptor positive （ER+/PR+,ER+/PR-,ER-/PR+） 4. HER2 negative（IHC 0 or +， FISH negative） 5. receive endocrine therapy only 6. enough FFPE samples within 10 years（3~6 10μm ） 7. patients with integrated medical records  Tumor cells <5% 2. Isolated RNA<500ng
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Fibroadenoma Atypical Ductal Hyperplasia Atypical Lobular Hyperplasia Lobular Carcinoma in Situ Flat Epithelial Atypia Phyllodes; Fibroadenoma Phyllodes Breast Tumor Radial Scar Breast Papilloma Complex Sclerosing Papillary Lesion of the Breast Women over age 18 with a core biopsy proven borderline or high-risk breast lesion that requires further excision for management based on the surgeon's assessment Informed consent must be obtained  Women who are considered high-risk based on a greater than 25% lifetime risk of breast cancer as per the IBIS (International Breast Cancer Intervention Study) Breast Cancer Risk Evaluation Tool Pathology that is felt to be discordant with imaging Extensive calcifications extending more than 20 mm and/or masses greater than 30 mm The following lesions will be excluded based on their increased risk of upstaging; lesions (other than fibroadenomas, phyllodes and papillomas) that are associated with a palpable mass, ADH (atypical ductal hyperplasia) with high-risk features (ADH with zonal necrosis, significant cytological atypia or more than 2 foci), LCIS (lobular carcinoma in situ) with high-risk features (associated with ADH, pleomorphic LCIS, zonal necrosis and > 4 foci) or discordant with imaging, papilloma with atypia, and spindle cell lesion (especially if there is atypia) Lesions that are suspicious for borderline or malignant Phyllodes, DCIS (ductal carcinoma in situ), invasive mammary carcinoma, or encapsulated papillary carcinoma Any lesion that either the radiologist, pathologist or surgeon feels is not amenable to VAPE or surgical excision
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Colorectal Cancer Age >= 18 years old Breast cancer requiring a treatment by paclitaxel or colorectal cancer requiring a treatment by oxaliplatine At least 8 chemotherapy cycles planned Able to understand, read and write French language Covered by a social insurance Dated and signed informed consent  Pre-existing neuropathy or history of neuropathy Psychological, family, sociological or georgraphical condition that may potentially compromise the adherence to study protocol and follow up Cohort 1: Patients presenting a Raynaud's syndrome (contra-indication to cold temperatures) Participation to clinical trial which may interfere with the evaluation of the main endpoints Pregnant or breastfeeding women
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Vacuum-assisted Biopsy Patient aged 18 years or older. 2. Written informed consent provided. 3. Triple negative or HER2-positive / ER-negative or HER2-positive / ER-positive breast tumours. 4. Patients eligible for breast conservation after NAC. 5. Patients with T2-T3 N0 invasive breast cancer initially treated by NAC to allow breast conservation, who have received a minimum of 6 cycles of adequate NAC +/ anti-HER2. 6. Clinical complete response after NAC. 7. Radiological (mammography, breast US, breast MRI) complete response after NAC. 8. Patients predicted to be node-negative at treatment initiation  Patient younger than 18 years old. 2. Pregnant or breastfeeding women. 3. Proven metastatic axillary or internal mammary chain lymph node involvement before NAC proven by biopsy or cytology. 4. Bilateral breast cancer. 5. Contraindication to MRI. 6. Contraindication to breast conservation 7. Patients with a BRCA mutation or other autosomal dominant high-penetrance genetic predisposition to breast cancer. 8. Patients with limitation of freedom or under guardianship 9. Inability for psychological reasons 10. Hypersensitivity to local anaesthesia 11. Initial imaging showing ACR6 micro calcifications and/or ACR6 non-mass enhancement associated to the index lesion
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Breast Cancer Breast Cancer Female HER2-positive Breast Cancer Breast Cancer Stage II Breast Cancer Stage III Women ages of 18 to 70 years old 2. Biopsy-accessible breast tumor of significant size for core needle biopsy/ultrasound measurable (≥ 2cm) 3. Patients with histologically confirmed carcinoma of the female breast with 3+ positive HER2 status by IHC 4. Clinical stages IIA -IIIC (AJCC 2009) 5. Chemotherapy-naïve patients (for this malignancy) 6. Performance status: ECOG performance status 0-1 (Appendix A) 7. Non-pregnant and not nursing. Women of childbearing potential must take the pregnancy test and must commit to receive LHRH agonist Zoladex (goserelin) for two years starting from the commencement of the study medications 8. Required Initial Laboratory Data. Adequate hematologic, renal and hepatic function, as defined by each of the following: 1. Granulocyte ≥ 1,500/μL 2. Platelet count ≥ 100,000/μL 3. Absolute neutrophil count (ANC) ≥ l500/μL 4. Hemoglobin ≥ 10g/dL 5. Bilirubin ≤ 1.5 x upper limit of normal 6. SGOT and SGPT < 2.5 x upper limit of normal 7. Creatinine within institutional normal limits or glomerular filtration rate ≥ 30 mL/min/1.73 m2 by CKD EPI equation (see http://mdrd.com/ for calculator) 9. ECHO: Baseline left ventricular ejection fraction of ≥ 55%  Pregnant or lactating women. Women of childbearing potential not using a reliable and appropriate contraceptive method. Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential. Patients of childbearing potential will agree to continue the use of acceptable form of contraception for 24 months from the date of last Herceptin administration. 2. Patients with distant metastasis (brain and/or visceral metastasis) 3. Serious, uncontrolled, concurrent infection(s). 4. Treatment for other carcinomas within the last 5 years, except non-melanoma skin cancer and treated cervical carcinoma in-situ (CCIS) 5. Participation in any investigational drug study within 4 weeks preceding the start of study treatment 6. Other serious uncontrolled medical conditions that the investigator feels might compromise study participation including but not limited to chronic or active infection, HIV-positive patient, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled Diabetes mellitus, or psychiatric illness/social situations that would limit compliance with study requirements. 7. Patients with HER2-negative disease
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Active Psoriatic Arthritis Diagnosed with PsA for at least 6 months before screening, and who meet the Classification for Psoriatic Arthritis (CASPAR) at screening Participants either (i) cannot have prior exposure to biologics (biologic-naïve) or (ii) have failed or been intolerant to 1 tumor necrosis factor -inhibitor (TNFi) (TNFi-experienced). Failure is defined as lack of response or loss of response with at least 3 months of therapy with an approved dose of a TNFi, as judged by the investigator. Failure must have occurred at least 2 months prior to Day 1 Participants have at least 1 confirmed greater than or equal to (>=) 2 centimeter (cm) lesion of plaque psoriasis at screening Participants have active arthritis as shown by a minimum of >= 3 swollen joints and >= 3 tender joints (66/68 joint counts) at screening and Day 1 High sensitivity C-reactive protein (hsCRP) >= 3milligram per liter (mg/L) at screening Women of Childbearing Potential (WOCBP) must have a negative serum or urine pregnancy test within 24 hours prior to the start of study treatment  Has non-plaque psoriasis (that is (i.e.), guttate, inverse, pustular, erythrodermic or drug-induced psoriasis) at screening or Day 1 Has any other autoimmune condition such as rheumatoid arthritis, etc. There are exceptions for inflammatory bowel disease or uveitis as follows: currently active disease is excluded but, a history of no longer active disease for at least 12 months (including not being on medication) is allowed Has active (i.e. currently symptomatic) fibromyalgia History or evidence of active infection and/or febrile illness within 7 days prior to Day 1 (example, bronchopulmonary, urinary, gastrointestinal, etc.) History of recent serious bacterial, fungal, or viral infections requiring hospitalization and intravenous (IV) antimicrobial treatment within 90 days prior to screening, or any infection requiring antimicrobial treatment within 15 days prior to Day 1 History of active tuberculosis (TB) prior to screening visit, regardless of completion of adequate treatment
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Transcranial Direct Current Stimulation Post Operative Pain Subjects who have scheduled elective spine surgery  Who has Cognitive dysfunction before surgery Who already has delirium before surgery Who has pain disorder ( like CRPS) Who cannot reveal the one's pain